Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome. (July 2019)

• Record Type: Journal Article
• Authors: Mizuta, Mao; Shimizu, Masaki; Inoue, Natsumi; Nakagishi, Yasuo; Yachie, Akihiro
• Is Part Of: Cytokine. Volume 119(2019)
• Page Start: 182
• Page End: 187
• Publication Date: 2019-07
• Subjects: Macrophage activation syndrome -- Systemic juvenile idiopathic arthritis -- Tocilizumab -- CXCL9; s-JIA systemic juvenile idiopathic arthritis -- MAS macrophage activation syndrome -- IL interleukin -- HLH hemophagocytic lymphohistiocytosis -- TCZ tocilizumab -- CRP C-reactive protein -- ELISA enzyme-linked immunosorbent assay -- HC healthy children -- sTNFR soluble tumor necrosis factor receptor -- IFN interferon; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2019.03.018
• Languages: English
• ISSNs: 1043-4666

Abstract

Highlights: Serum CXCL9 levels correlated positively with disease activity of s-JIA associated MAS. Monitoring of serum CXCL9 is useful for the evaluation of disease activity in s-JIA associated MAS. The expression of numerous inflammatory cytokines including CXCL9 was altered in patients receiving tocilizumab. Abstract: To clarify cytokines involved in the development of systemic juvenile idiopathic arthritis (s-JIA) associated macrophage activation syndrome (MAS) and to identify the serum biomarkers for the diagnosis of s-JIA associated MAS, we employed an antibody array that simultaneously detects 174 cytokines. Fifteen s-JIA patients including 5 patients receiving tocilizumab (TCZ) were analyzed. The levels of five cytokines were significantly elevated in MAS phase compared to those in the active phase of s-JIA. CXCL9 showed the most significant increase following the development of s-JIA associated MAS. Next, to confirm clinical significance of serum CXCL9 levels as a biomarker for s-JIA associated MAS, serum CXCL9 levels in 56 patients with s-JIA including 20 with MAS were analyzed. Results were compared with the clinical features of s-JIA associated MAS. Serum CXCL9 levels correlated positively with disease activity. Monitoring of serum CXCL9 is useful for the evaluation of disease activity in s-JIA associated MAS.